A critical review of methodologies used in pharmaceutical pricing policy analyses
Open Access
- 13 March 2022
- journal article
- review article
- Published by Elsevier in Health Policy
- Vol. 134, 104576
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Impact of STROBE Statement Publication on Quality of Observational Study Reporting: Interrupted Time Series versus Before-After AnalysisPLOS ONE, 2013
- The effects of new pricing and copayment schemes for pharmaceuticals in South KoreaHealth Policy, 2012
- The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitorsHealth Economics Review, 2011
- The Short-Term Impact of Ontario's Generic Pricing ReformsPLOS ONE, 2011
- Assessing the effects of drug price reduction policies on older people in TaiwanHealth Services Management Research, 2011
- Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004BMC Health Services Research, 2010
- Alternatives to randomisation in the evaluation of public health interventions: design challenges and solutions: Table 1Journal of Epidemiology and Community Health, 2009
- 'Doing' health policy analysis: methodological and conceptual reflections and challengesHealth Policy and Planning, 2008
- The terrain of health policy analysis in low and middle income countries: a review of published literature 1994-2007Health Policy and Planning, 2008
- The impact of generic reference pricing interventions in the statin marketHealth Policy, 2007